Tazorac Side Effects

Generic name: tazarotene topical

Note: This document contains side effect information about tazarotene topical. Some of the dosage forms listed on this page may not apply to the brand name Tazorac.

Some side effects of Tazorac may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to tazarotene topical: topical cream, topical foam, topical gel

Get emergency medical help if you have any of these signs of an allergic reaction while taking tazarotene topical (the active ingredient contained in Tazorac) hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using tazarotene topical and call your doctor at once if you have a serious side effect such as:

• severe skin irritation (burning, stinging, itching) after applying this medication;

• severe redness or discomfort; or

• swelling, warmth, oozing, or other signs of skin infection.

Less serious side effects of tazarotene topical may include:

• mild burning, stinging, or itching;

• mild pain, redness, or irritation; or

• skin dryness or peeling.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to tazarotene topical: topical cream, topical foam, topical gel

Dermatologic

Dermatologic side effects associated with Avage(R) topical cream have included desquamation (40%), erythema (34%), burning sensation (26%), dry skin (16%), skin irritation (10%), pruritus (10%), irritant contact dermatitis (8%), stinging (3%), acne (3%), rash (3%), and cheilitis (1%). Pruritus, erythema, and burning have been reported (in descending order) with Tazorac(R) topical cream in 10% to 23% of psoriasis patients. Desquamation, dry skin, erythema, and burning sensation have been reported (in descending order) with Tazorac(R) topical cream in 10% to 30% of acne patients. Irritation, desquamation, stinging, contact dermatitis, dermatitis, eczema, worsening of psoriasis, skin pain, rash, dry skin, and skin inflammation have been reported (in descending order) with Tazorac(R) topical cream in greater than 1% to less than 10% of psoriasis patients. Pruritus, irritation, face pain, and stinging have been reported with Tazorac(R) topical cream in 1% to 5% of acne patients. Dermatitis (less than 1%), impetigo (less than 1%), pruritus (less than 1%), local skin reactions, dryness, erythema, peeling, burning/stinging, and itching have been reported with tazarotene topical (the active ingredient contained in Tazorac) foam. Pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, and skin pain have been reported (in descending order) with tazarotene topical gel in 10% to 30% of psoriasis patients. Desquamation, burning/stinging, dry skin, erythema, and pruritus have been reported (in descending order) with tazarotene topical gel in 10% to 30% of acne patients. Rash, desquamation, irritant contact dermatitis, skin inflammation, fissuring, bleeding, and dry skin have been reported with tazarotene topical gel in 1% to 10% of psoriasis patients. Irritation, skin pain, fissuring, and skin discoloration have been reported with tazarotene topical gel in 1% to 10% of acne patients. Psoriasis worsening and sun-induced erythema have also been reported with tazarotene topical gel in psoriasis patients. Blister, rash, skin discoloration (including skin hyperpigmentation or skin hypopigmentation), and pain have been reported during postmarketing experience with tazarotene topical gel.

Local

Local side effects associated with tazarotene topical (the active ingredient contained in Tazorac) foam have included application site irritation (14%), application site dryness (7%), application site erythema (6%), application site exfoliation (6%), application site pain (1%), application site photosensitivity (including sunburn; 1%), application site pruritus (1%), application site dermatitis (1%), and application site reactions (including discoloration, discomfort, edema, rash, and swelling; less than 1%). Localized edema has been reported with tazarotene topical gel in 1% to 10% of acne patients.

Metabolic

Metabolic side effects associated with Tazorac(R) topical cream have included hypertriglyceridemia (greater than 1% to less than 10%).

Other

Other side effects associated with Tazorac(R) topical cream have included peripheral edema (greater than 1% to less than 10%).

Ocular

Ocular side effects associated with Avage(R) topical cream have included edema, irritation, and inflammation directly related to the eye or eyelid.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.